AceReport Image
TRAUMA
OTA: Indomethacin is no better than placebo for preventing heterotopic ossification

98 patients with an acetabular fracture were included in a study to examine the effects of indomethacin on the prevention of heterotopic ossification (HO). Patients underwent open reduction and internal fixation through a Kocher-Langenbeck approach. They were then randomized to receive placebo for 6 weeks (group 1), 3 days of indomethacin followed by placebo for a total of 6 weeks (group 2), 1 week of indomethacin followed by 5 weeks of placebo (group 3), or 6 weeks of indomethacin (group 4). Over 1 year, the incidence of HO based on radiographic analysis was significantly higher in group 1 than in group 2 and 3. However, the groups did not differ significantly with respect to CT volumetric analyses, the occurrence of clinically significant HO, incidence of posterior wall nonunion, and range of motion. Pain scores were significantly higher in patients who had posterior wall non-union than those who did not. The results did not provide any evidence for the effectiveness of indomethacin, and the medication, therefore, cannot be recommended for the prevention of HO.

Unlock the full ACE Report

You have access to {0} free articles per month.
Click below to unlock and view this {1}
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
{0} of {1} free articles

Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.

Upgrade Now
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade Account
Upgrade
Search
Close Search Window
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Cite this Ace Report

OrthoEvidence. OTA: Indomethacin is no better than placebo for preventing heterotopic ossification. ACE Report. 2013;3(8):296. Available from: https://myorthoevidence.com/AceReport/Report/

Copy Citation
Share this Ace Report